Share of global biopharmaceutical pipeline vs Autoimmune cell therapy and T-cell engager trial starts in China
In 2025, share of global biopharmaceutical pipeline in China was 30%; autoimmune cell therapy and T-cell engager trial starts was 76.
Change the pair
Compare different indicators
The series
Over time
China, annual figures, spaced by time . Different units, drawn on separate scales . Read the values, not the heights.
Share of global biopharmaceutical pipeline
Unit: % · 2 observations
Autoimmune cell therapy and T-cell engager trial starts
Unit: count · 6 observations
Shared periods
Side by side
Only one period is published for both series in China as annual figures on the same basis. Comparing anything else would mean comparing different periods.
Provenance
Where these numbers come from
Share of global biopharmaceutical pipeline
Proportion of global biopharmaceutical research and development pipeline assets originating from a specific country or region.
2 observations charted in China · source organisations: State Council
Autoimmune cell therapy and T-cell engager trial starts
Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
6 observations charted in China · source organisations: ClinicalTrials.gov
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring